Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 27, 2016
Event: Receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is regulatory in nature. On December 27, 2016, the Company received a CRL from the FDA regarding its New Drug Application (NDA) for Primatene® Mist (epinephrine inhalation aerosol). A CRL indicates that the FDA has not approved the application in its current form and outlines deficiencies that must be addressed.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for further details but does not include specific management commentary, updated guidance, or financial outlook within the text of this 8-K.
Risks and Contingencies: The receipt of a CRL represents a significant regulatory risk, potentially delaying the commercialization of Primatene® Mist until the identified issues are resolved and a resubmission is approved.
Key Facts for Investor Verification
- Verify the specific deficiencies cited in the FDA's Complete Response Letter for Primatene® Mist.
- Review the attached press release (Exhibit 99.1) for management's immediate response and potential timeline for resubmission.
- Assess the potential impact of this delay on the Company's projected revenue and product pipeline.
- Confirm if this event triggers any material adverse change clauses in existing debt or partnership agreements.